BRAF and ependymoma: We show that most cases will likely be resolved by careful histopathologic analysis and the use of immunohistochemical stains, including surrogate stains for histone 3, IDH1 and BRAF mutations, and subtype-specific stains for ependymoma and medulloblastoma.